Literature DB >> 30028187

Predicting the dose absorbed by organs at risk during intensity modulated radiation therapy for nasopharyngeal carcinoma.

Haowen Pang1, Xiaoyang Sun1, Bo Yang1, Jingbo Wu1.   

Abstract

OBJECTIVE: : To develop a model for predicting the dose absorbed by organ at risk (OAR) during intensity modulated radiation therapy for nasopharyngeal carcinoma (NPC).
METHODS: : 55 patients underwent intensity modulated radiation therapy for NPC. The OARs were divided into several suborgans, and SPSS software was used to evaluate multiple linear method for fitting the normalized volume for each suborgan, normalized mean dose (Dmean) Dnm (Dnm = Dmean/Dprescription), and normalized D10%-D100% values Dn10%-n100%(Dn10%-n100% = D10%-D100%/Dprescription) for each OAR. Based on the Matlab software, the predicted Dn10%-n100% value was fitted to obtain the predicted DVH curve.
RESULTS: : The multiple linear fitting formulas revealed significant results for the oral cavity Dn100% (p = 0.017), the parotid gland Dn100% (p = 0.001), and the remaining OAR (all p < 0.0001). The correlation coefficients and p values indicated that the fitting formula was a good fit. The p values for the White test show that the prediction model is robust. This method was successfully used for verification cases.
CONCLUSION: : The present study provided a simple and effective model for predicting the dose absorbed by OAR for NPC. ADVANCES IN KNOWLEDGE:: This method is a relatively simple mathematical model, just use prescription dose and V0-Vn to predict the Dmean and D10%-100%, which predict does not require buying new modules of treatment planning software or extracting the distance of each sampling point of the OAR with the dose information.

Entities:  

Mesh:

Year:  2018        PMID: 30028187      PMCID: PMC6319853          DOI: 10.1259/bjr.20170289

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  20 in total

1.  Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.

Authors:  Nancy Lee; Jonathan Harris; Adam S Garden; William Straube; Bonnie Glisson; Ping Xia; Walter Bosch; William H Morrison; Jeanne Quivey; Wade Thorstad; Christopher Jones; K Kian Ang
Journal:  J Clin Oncol       Date:  2009-06-29       Impact factor: 44.544

2.  A planning quality evaluation tool for prostate adaptive IMRT based on machine learning.

Authors:  Xiaofeng Zhu; Yaorong Ge; Taoran Li; Danthai Thongphiew; Fang-Fang Yin; Q Jackie Wu
Journal:  Med Phys       Date:  2011-02       Impact factor: 4.071

3.  Cross-institutional knowledge-based planning (KBP) implementation and its performance comparison to Auto-Planning Engine (APE).

Authors:  Binbin Wu; Martijn Kusters; Martina Kunze-Busch; Tim Dijkema; Todd McNutt; Giuseppe Sanguineti; Karl Bzdusek; Anatoly Dritschilo; Dalong Pang
Journal:  Radiother Oncol       Date:  2017-02-13       Impact factor: 6.280

4.  Predicting dose-volume histograms for organs-at-risk in IMRT planning.

Authors:  Lindsey M Appenzoller; Jeff M Michalski; Wade L Thorstad; Sasa Mutic; Kevin L Moore
Journal:  Med Phys       Date:  2012-12       Impact factor: 4.071

5.  Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.

Authors:  Nancy Y Lee; Qiang Zhang; David G Pfister; John Kim; Adam S Garden; James Mechalakos; Kenneth Hu; Quynh T Le; A Dimitrios Colevas; Bonnie S Glisson; Anthony Tc Chan; K Kian Ang
Journal:  Lancet Oncol       Date:  2011-12-15       Impact factor: 41.316

6.  Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy.

Authors:  Miao-Fen Chen; Chih-Jen Tseng; Ching-Cheng Tseng; Yuen-Chun Kuo; Chun-Yen Yu; Wen-Cheng Chen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-04-01       Impact factor: 7.038

7.  Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series.

Authors:  Shaojun Lin; Jianji Pan; Lu Han; Xiuchun Zhang; Xiyi Liao; Jiade J Lu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-11       Impact factor: 7.038

8.  Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma.

Authors:  Anne W M Lee; Kam Ying Lau; Wai Man Hung; Wai Tong Ng; Michael C H Lee; Cheuk Wai Choi; Connie C C Chan; Raymond Tung; Peter T C Cheng; Tsz Kok Yau
Journal:  Radiother Oncol       Date:  2008-03-10       Impact factor: 6.280

9.  Is it possible for knowledge-based planning to improve intensity modulated radiation therapy plan quality for planners with different planning experiences in left-sided breast cancer patients?

Authors:  Juanqi Wang; Weigang Hu; Zhaozhi Yang; Xiaohui Chen; Zhiqiang Wu; Xiaoli Yu; Xiaomao Guo; Saiquan Lu; Kaixuan Li; Gongyi Yu
Journal:  Radiat Oncol       Date:  2017-05-22       Impact factor: 3.481

10.  Can knowledge-based DVH predictions be used for automated, individualized quality assurance of radiotherapy treatment plans?

Authors:  Jim P Tol; Max Dahele; Alexander R Delaney; Ben J Slotman; Wilko F A R Verbakel
Journal:  Radiat Oncol       Date:  2015-11-19       Impact factor: 3.481

View more
  2 in total

1.  Organ-at-risk dose prediction using a machine learning algorithm: Clinical validation and treatment planning benefit for lung SBRT.

Authors:  N Patrik Brodin; Leslie Schulte; Christian Velten; William Martin; Sydney Shen; Jin Shen; Amar Basavatia; Nitin Ohri; Madhur K Garg; Colin Carpenter; Wolfgang A Tomé
Journal:  J Appl Clin Med Phys       Date:  2022-04-23       Impact factor: 2.243

2.  Support Vector Machine Model Predicts Dose for Organs at Risk in High-Dose Rate Brachytherapy of Cervical Cancer.

Authors:  Ping Zhou; Xiaojie Li; Hao Zhou; Xiao Fu; Bo Liu; Yu Zhang; Sheng Lin; Haowen Pang
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.